Changchun ProteLight Pharmaceutical & Biotechnology Co., Ltd. was founded as research and development company.
2009
Established Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd.(ProteLight Pharma)
2011
ProteLight Pharma officially acquired Changchun ProteLight as a wholly-owned R&D subsidiary
2012
The antimicrobial peptide PL-5 spray project was selected into the “12th Five-Year Plan” major new drug innovative manufacture project of the National Health Commission
2014
Selected as "2014 China's Most Potential Seed Enterprises" by Ernst & Young
2016-2020
+
2016
The antimicrobial peptide PL-5 spray obtained clinical approval for a new drug, becoming the first innovative antimicrobial peptide drug to enter human clinical trials in China
2017
Two national category I innovative drugs, the antimicrobial peptide PL-5 spray project and the antimicrobial peptide PL-18 suppository project were selected into the "13th Five-Year Plan" major new drug innovative manufacture projects of the National Health Commission
2019
ProteLight Pharmaceutical Industry Base forally opens Honored as "Potential Unicorn Enterprise of Sunan National Innovation Park " Honored as “Wuxin Prospective Unicorn Enterprise”
2020
Established Nanjing Denovo Pharmaceutical Co., Ltd. (a wholly-owned R&D subsidiary) Established Jiangsu Putai Pharmaceutical Technology Co., Ltd.(a wholly-owned subsidiary of disinfection products)
2021-2025
+
2021
Established ProteLight Medical Holdings (Hong Kong) Co., Ltd. (a wholly-owned subsidiary of overseas business)
